Antistreptococcal_JJ Activity_NN of_IN Telithromycin_NP Compared_VBN with_IN Seven_CD Other_JJ Drugs_NNS in_IN Relation_NN to_TO Macrolide_NP Resistance_NP Mechanisms_NNS in_IN Russia_NP The_DT susceptibilities_NNS of_IN 468_CD recent_JJ Russian_JJ clinical_JJ Streptococcus_NP pneumoniae_NNS isolates_NNS and_CC 600_CD Streptococcus_NP pyogenes_NNS isolates_NNS ,_, from_IN 14_CD centers_NNS in_IN Russia_NP ,_, to_TO telithromycin_NN ,_, erythromycin_NN ,_, azithromycin_NP ,_, clarithromycin_NP ,_, clindamycin_NN ,_, levofloxacin_NP ,_, quinupristin-dalfopristin_NP ,_, and_CC penicillin_NN G_NN were_VBD tested_VBN ._SENT Penicillin-nonsusceptible_NP S._NP pneumoniae_NNS strains_NNS were_VBD rare_JJ except_IN in_IN Siberia_NP ,_, where_WRB their_PP$ prevalence_NN rate_NN was_VBD 13.5_CD %_NN :_: most_RBS were_VBD penicillin_NN intermediate_JJ ,_, but_CC for_IN three_CD strains_NNS (_( two_CD from_IN Smolensk_NP and_CC one_CD from_IN Novosibirsk_NP )_) the_DT MICs_NN of_IN penicillin_NN G_NN were_VBD 4_CD or_CC 8_CD mug/ml_NN ._SENT Overall_RB ,_, 2.5_CD %_NN of_IN S._NP pneumoniae_NNS isolates_NNS were_VBD resistant_JJ to_TO erythromycin_NN ._SENT Efflux_NN was_VBD the_DT prevalent_JJ resistance_NN mechanism_NN (_( five_CD strains_NNS ;_: 41.7_CD %_NN )_) ,_, followed_VBN by_IN ribosomal_JJ methylation_NN encoded_VBN by_IN constitutive_JJ erm(B)_NN ,_, which_WDT was_VBD found_VBN in_IN four_CD isolates_NNS ._SENT Ribosomal_JJ mutation_NN was_VBD the_DT mechanism_NN of_IN macrolide_NN resistance_NN in_IN three_CD isolates_NNS ;_: one_CD erythromycin-resistant_JJ S._NP pneumoniae_NNS isolate_NN had_VBD an_DT A2059G_NP mutation_NN in_IN 23S_JJ rRNA_NN ,_, and_CC two_CD isolates_NNS had_VBD substitution_NN of_IN GTG_NP by_IN TPS_NP at_IN positions_NNS 69_CD to_TO 71_CD in_IN ribosomal_JJ protein_NN L4_NP ._SENT All_DT S._NP pyogenes_NNS isolates_NNS were_VBD susceptible_JJ to_TO penicillin_NN ,_, and_CC 11_CD %_NN were_VBD erythromycin_NN resistant_NN ._SENT Ribosomal_JJ methylation_NN was_VBD the_DT most_RBS common_JJ resistance_NN mechanism_NN for_IN S._NP pyogenes_NNS (_( 89.4_CD %_NN )_) ._SENT These_DT methylases_NNS were_VBD encoded_VBN by_IN erm(A)_NP [_SYM subclass_NN erm(TR)_NN ]_SYM genes_NNS ,_, and_CC their_PP$ expression_NN was_VBD inducible_JJ in_IN 96.6_CD %_NN of_IN isolates_NNS ._SENT The_DT rest_NN of_IN the_DT erythromycin-resistant_JJ Russian_JJ S._NP pyogenes_NNS isolates_NNS (_( 7.6_CD %_NN )_) had_VBD an_DT efflux_NN resistance_NN mechanism_NN ._SENT Telithromycin_NP was_VBD active_JJ against_IN 100_CD %_NN of_IN pneumococci_NNS and_CC 99.2_CD %_NN of_IN S._NP pyogenes_NNS ,_, and_CC levofloxacin_NN and_CC quinupristin-dalfopristin_NN were_VBD active_JJ against_IN all_DT isolates_NNS of_IN both_DT species_NN ._SENT The_DT problem_NN of_IN pneumococcal_JJ strains_NNS resistant_JJ to_TO beta-lactams_NNS ,_, macrolides_NNS ,_, and_CC other_JJ compounds_NNS has_VBZ spread_VBN worldwide_RB to_TO such_PDT a_DT degree_NN that_IN we_PP are_VBP in_IN the_DT midst_NN of_IN a_DT pandemic_NN ._SENT Across_IN the_DT world_NN ,_, the_DT incidence_NN of_IN pneumococcal_JJ strains_NNS that_WDT are_VBP fully_RB resistant_JJ to_TO penicillin_NN G_NP is_VBZ rising_VBG relative_JJ to_TO strains_NNS with_IN intermediate_JJ penicillin_NN resistance_NN (_( ,_, ,_, ;_: A._NP L._NP Barry_NP ,_, P._NP C._NP Fuchs_NP ,_, and_CC S._NP D._NP Brown_NP ,_, Letter_NP ,_, J._NP Antimicrob_NP ._SENT Chemother_NP ._SENT 40:139-140_CD ,_, 1997_CD )_) ._SENT The_DT problem_NN is_VBZ complicated_VBN by_IN the_DT fact_NN that_IN the_DT higher_JJR the_DT penicillin_NN G_NP MIC_NP for_IN pneumococci_NNS is_VBZ ,_, the_DT higher_JJR the_DT prevalence_NN of_IN macrolide_NN resistance_NN is_VBZ ._SENT In_IN the_DT United_NP States_NPS ,_, <5%_of 50_CD %_NN of_IN penicillin-resistant_JJ strains_NNS are_VBP macrolide_RB resistant_JJ ._SENT This_DT relationship_NN between_IN penicillin_NN G_NN and_CC macrolide_NN resistance_NN is_VBZ not_RB the_DT same_JJ in_IN all_DT countries_NNS ._SENT For_IN example_NN ,_, approximately_RB 50_CD %_NN of_IN Spanish_JJ strains_NNS with_IN intermediate_JJ resistance_NN to_TO penicillin_NN G_NN are_VBP macrolide_RB resistant_JJ ,_, and_CC in_IN Northern_NP Italy_NP ,_, where_WRB the_DT rate_NN of_IN penicillin_NN resistance_NN is_VBZ approximately_RB 5_CD %_NN ,_, 45_CD %_NN of_IN penicillin-susceptible_JJ strains_NNS are_VBP resistant_JJ to_TO macrolides_NNS ._SENT Pneumococcal_JJ strains_NNS resistant_JJ to_TO beta-lactams_NNS are_VBP a_DT particular_JJ problem_NN in_IN Central_NP and_CC Eastern_NP Europe_NP ,_, especially_RB in_IN Hungary_NP ,_, Slovakia_NP ,_, Romania_NP ,_, and_CC Bulgaria_NP ._SENT Although_IN Streptococcus_NP pyogenes_NNS strains_NNS have_VBP not_RB yet_RB developed_VBN resistance_NN to_TO penicillin_NN G_NP ,_, macrolide_NN resistance_NN in_IN these_DT strains_NNS is_VBZ quite_RB widespread_JJ throughout_IN the_DT world_NN ,_, particularly_RB in_IN Europe_NP ._SENT Although_IN the_DT prevalence_NN of_IN macrolide_NN resistance_NN in_IN the_DT United_NP States_NPS has_VBZ been_VBN described_VBN as_IN being_VBG low_JJ ,_, a_DT recent_JJ report_NN has_VBZ described_VBN an_DT increase_NN in_IN macrolide_NN resistance_NN in_IN the_DT San_NP Francisco_NP Bay_NP area_NN ._SENT High_JJ prevalence_NN of_IN erythromycin_NN resistance_NN in_IN pneumococci_NNS and_CC group_NN A_DT streptococci_NNS in_IN many_JJ Central_NP and_CC Eastern_NP European_NP countries_NNS has_VBZ already_RB been_VBN documented_VBN by_IN our_PP$ group_NN ._SENT Macrolide_NN resistance_NN among_IN Streptococcus_NP pneumoniae_NP and_CC S._NP pyogenes_NNS is_VBZ usually_RB because_IN of_IN the_DT ribosomal_JJ methylation_NN of_IN 23S_JJ rRNA_NN [_SYM erm(B)_NN or_CC erm(A)_NNS ]_SYM or_CC active_JJ efflux_NN of_IN these_DT antibacterials_NN [_SYM mef(A)_NN ]_SYM ._SENT Recently_RB ,_, ribosomal_JJ mutations_NNS in_IN 23S_JJ rRNA_NN and_CC ribosomal_JJ L4_NP proteins_NNS that_WDT confer_VBP macrolide_NN resistance_NN were_VBD described_VBN in_IN clinical_JJ strains_NNS of_IN S._NP pneumoniae_NNS ._SENT This_DT study_NN compared_VBN the_DT activity_NN of_IN telithromycin_NN with_IN activities_NNS of_IN erythromycin_NN ,_, azithromycin_NP ,_, clarithromycin_NP ,_, clindamycin_NN ,_, penicillin_NN G_NP ,_, quinupristin-dalfopristin_NP ,_, and_CC levofloxacin_NN against_IN S._NP pneumoniae_NP and_CC S._NP pyogenes_NNS organisms_NNS from_IN centers_NNS throughout_IN the_DT Russian_NP Federation_NP ._SENT Macrolide_NP resistance_NN mechanisms_NNS of_IN erythromycin-resistant_JJ isolates_NNS were_VBD determined_VBN ._SENT Bacteria_NNS and_CC antimicrobials_NNS ._SENT |_SYM Isolates_NP were_VBD isolated_VBN consecutively_RB from_IN the_DT various_JJ centers_NNS during_IN 2000_CD and_CC 2001_CD and_CC were_VBD screened_VBN using_VBG optochin_NN and_CC bacitracin_NN disk_NN methodology_NN ._SENT For_IN the_DT purpose_NN of_IN this_DT study_NN ,_, the_DT Russian_NP Federation_NP was_VBD divided_VBN into_IN five_CD regions_NNS :_: (_( i_NP )_) central_JJ (_( Moscow_NP ,_, Kazan_NP ,_, Ryazan_NP ,_, Nizhnij_NP Novgorod_NP ,_, and_CC Yaroslavl_NP )_) ;_: (_( ii_NNS )_) northwest_RB (_( Smolensk_NP and_CC St._NP Petersburg_NP )_) ;_: (_( iii_NP )_) south_NN (_( Krasnodar_NP )_) ;_: (_( iv_NP )_) Urals_NP (_( Ekaterinburg_NP and_CC Chelyabinsk_NP )_) ;_: and_CC (_( v_NN )_) Siberia_NP (_( Tomsk_NP ,_, Irkutsk_NP ,_, Tumen_NP ,_, and_CC Novosibirsk_NP )_) ._SENT Organisms_NNS were_VBD then_RB transported_VBN to_TO Hershey_NP Medical_NP Center_NP ,_, Hershey_NP ,_, Pa._NP ,_, where_WRB they_PP were_VBD stored_VBN frozen_VBN in_IN double-strength_JJ skim_NN milk_NN (_( Difco_NP Laboratories_NP ,_, Detroit_NP ,_, Mich._NP )_) at_IN -70C_NN until_IN use_NN ._SENT Before_IN testing_NN ,_, S._NP pneumoniae_NP and_CC S._NP pyogenes_NNS cultures_NNS were_VBD checked_VBN for_IN purity_NN ._SENT The_DT identity_NN of_IN S._NP pneumoniae_NNS strains_NNS was_VBD confirmed_VBN by_IN optochin_NN and_CC ,_, as_IN necessary_JJ ,_, by_IN bile_NN solubility_NN testing_NN ._SENT The_DT confirmation_NN of_IN identity_NN of_IN S._NP pyogenes_NNS was_VBD done_VBN by_IN bacitracin_NN disk_NN (_( Becton_NP Dickinson_NP ,_, Cockeysville_NP ,_, Md._NP )_) and_CC ,_, as_IN necessary_JJ ,_, by_IN latex_NN agglutination_NN ._SENT Telithromycin_NP ,_, quinupristin-dalfopristin_NP ,_, levofloxacin_NP ,_, erythromycin_NN ,_, azithromycin_NN ,_, and_CC clarithromycin_NN were_VBD obtained_VBN from_IN Aventis_NP Pharma_NP ,_, Infectious_NP Division_NP ,_, Romainville_NP ,_, France_NP ._SENT Clindamycin_NN and_CC penicillin_NN G_NN were_VBD purchased_VBN from_IN Sigma_NP Inc._NP ,_, St_NP Louis_NP ,_, Mo._NP Susceptibility_NP testing_NN ._SENT |_SYM Susceptibility_NP testing_NN was_VBD performed_VBN by_IN agar_NN dilution_NN on_IN Mueller-Hinton_NP agar_NN (_( Difco_NP )_) supplemented_VBD with_IN 5_CD %_NN sheep_NN blood_NN ._SENT Inocula_NNS were_VBD prepared_VBN by_IN suspending_VBG growth_NN from_IN overnight_JJ cultures_NNS in_IN sterile_JJ Mueller-Hinton_NP broth_NN to_TO a_DT turbidity_NN equal_JJ to_TO a_DT 0.5_CD McFarland_NP standard_NN ._SENT A_DT 1:10_CD dilution_NN was_VBD made_VBN in_IN Mueller-Hinton_NP broth_NN so_RB that_IN the_DT final_JJ inocula_NNS contained_VBD 5_CD x_SYM 104_CD CFU/spot_NN ._SENT Plates_NNS were_VBD inoculated_VBN with_IN a_DT Steers_NP replicator_NN using_VBG 3-mm-diameter_JJ inoculating_VBG pins_NNS ,_, delivering_VBG 1_CD mul_NN of_IN inoculum_NN ,_, and_CC incubated_VBD overnight_RB at_IN 35C_JJ in_IN air_NN ._SENT The_DT lowest_JJS concentration_NN of_IN antimicrobial_NN showing_VBG no_DT growth_NN was_VBD read_VBN as_IN the_DT MIC_NN ._SENT Standard_JJ quality_NN control_NN strains_NNS ,_, including_VBG Staphylococcus_NP aureus_NN ATCC_NP 29213_CD and_CC S._NP pneumoniae_NNS ATCC_NP 49619_CD ,_, were_VBD included_VBN with_IN each_DT run_NN ._SENT Breakpoints_NNS used_VBN were_VBD those_DT approved_VBN by_IN the_DT National_NP Committee_NP for_IN Clinical_NP Laboratory_NP Standards_NPS for_IN S._NP pneumoniae_NP and_CC S._NP pyogenes_NNS except_IN for_IN telithromycin_NN ,_, for_IN which_WDT European_JJ breakpoints_NNS were_VBD used_VBN :_: susceptible_JJ ,_, <=0.5_mug/ml; 2_CD mug/ml_NN (_( C._NP J._NP Soussy_NP ,_, F._NP Goldstein_NP ,_, A._NP Bryskier_NP ,_, H._NP Drugeon_NP ,_, J._NP Andrews_NPS ,_, F._NP Baquero_NP ,_, O._NP Cars_NPS ,_, D._NP Felmingham_NP ,_, B._NP Olsson-Liljequist_NP ,_, A._NP Rodloff_NP ,_, G._NP C._NP Schito_NP ,_, B._NP Wiedemann_NP ,_, and_CC R._NP Wise_NP ,_, Abstr_NP ._SENT 40th_JJ Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstr_NN ._SENT 321_CD ,_, 2000_CD )_) ._SENT Determination_NN of_IN macrolide_NN resistance_NN mechanisms_NNS and_CC gene_NN sequencing_VBG ._SENT |_SYM Isolates_NP found_VBD to_TO be_VB resistant_JJ to_TO macrolides_NNS were_VBD screened_VBN for_IN their_PP$ resistance_NN mechanisms_NNS ._SENT Primers_NNS and_CC PCR_NP conditions_NNS used_VBN for_IN this_DT work_NN have_VBP been_VBN described_VBN previously_RB :_: those_DT for_IN mef(A)_NN and_CC erm(B)_NN were_VBD described_VBN by_IN Sutcliffe_NP et_FW al._FW ,_, those_DT for_IN erm(A)_NN were_VBD described_VBN by_IN Pankuch_NP et_FW al._FW ,_, and_CC those_DT for_IN 23S_JJ rRNA_NN and_CC L4_JJ protein_NN genes_NNS were_VBD described_VBN by_IN Tait-Kamradt_NP and_CC coworkers_NNS ._SENT The_DT PCR_NP products_NNS after_IN amplification_NN of_IN domain_NN V_NN of_IN 23S_JJ rRNA_NN ,_, and_CC entire_JJ genes_NNS encoding_VBG L4_NP and_CC L22_NP ,_, were_VBD purified_VBN using_VBG a_DT QIAquick_NP PCR_NP purification_NN kit_NN (_( QIAGEN_NP ,_, Valencia_NP ,_, Calif._NP )_) and_CC sequenced_JJ using_VBG an_DT Applied_NP Biosystems_NP model_NN 373_CD DNA_NN sequencer_NN ._SENT All_DT erythromycin-resistant_JJ strains_NNS were_VBD screened_VBN for_IN the_DT ability_NN to_TO induce_VB resistance_NN by_IN the_DT double-disk_NN diffusion_NN test_NN using_VBG erythromycin_NN and_CC clindamycin_NN disks_NNS ._SENT PFGE_NP ._SENT |_SYM Pulsed-field_NP gel_NN electrophoresis_NN (_( PFGE_NP )_) was_VBD performed_VBN using_VBG a_DT CHEF_NP DR_NP III_NP apparatus_NN (_( Bio-Rad_NP ,_, Hercules_NP ,_, Calif._NP )_) as_RB described_VBD previously_RB ._SENT FIG._NN 1_CD ._SENT |_SYM Geographic_NP locations_NNS of_IN Russian_JJ centers_NNS providing_VBG S._NP pneumoniae_NP Geographic_NP locations_NNS of_IN Russian_JJ centers_NNS providing_VBG S._NP pneumoniae_NP and_CC S._NP pyogenes_NNS isolates_VBZ for_IN this_DT study_NN ._SENT S._NP pneumoniae_NNS ._SENT |_SYM S._NP pneumoniae_NNS strains_NNS were_VBD isolated_VBN predominantly_RB from_IN respiratory_JJ sources_NNS (_( 61_CD %_NN )_) ._SENT Most_JJS of_IN the_DT pneumococci_NNS were_VBD from_IN sputum_NN (_( 51_CD %_NN )_) ,_, ear_NN (_( 11.5_CD %_NN )_) ,_, and_CC cerebrospinal_JJ fluid_NN (_( 11.1_CD %_NN )_) ._SENT Patient_JJ ages_NNS varied_VBN from_IN 1_CD month_NN to_TO 85_CD years_NNS ._SENT The_DT peak_NN age_NN distribution_NN was_VBD found_VBN in_IN children_NNS 2_CD to_TO 10_CD years_NNS old_JJ ._SENT Susceptibilities_NNS of_IN the_DT pneumococcal_JJ strains_NNS tested_VBN are_VBP shown_VBN in_IN Tables_NP and_NP ._SENT Raised_VBN penicillin_NN G_NP MICs_NP were_VBD found_VBN at_IN a_DT prevalence_NN of_IN <=5%_in =2.0_JJ mug/ml_NN ._SENT However_RB ,_, three_CD penicillin_NN G-resistant_JJ pneumococcal_JJ isolates_NNS for_IN which_WDT the_DT MICs_NP were_VBD 4.0_CD to_TO 8.0_CD mug/ml_NN were_VBD isolated_VBN ._SENT Two_CD isolates_NNS from_IN Smolensk_NP ,_, for_IN which_WDT the_DT MICs_NN of_IN penicillin_NN G_NN were_VBD 4_CD and_CC 8.0_CD mug/ml_NN ,_, were_VBD from_IN the_DT lung_NN tissue_NN of_IN a_DT 4-month-old_JJ infant_NN and_CC the_DT sinus_NN of_IN a_DT 40-year-old_JJ patient_NN ,_, respectively_RB ;_: these_DT strains_NNS were_VBD resistant_JJ to_TO macrolides_NNS but_CC susceptible_JJ to_TO clindamycin_NN and_CC telithromycin_NN ._SENT The_DT other_JJ strain_NN ,_, for_IN which_WDT the_DT MIC_NN of_IN penicillin_NN G_NN was_VBD 8.0_CD mug/ml_NN ,_, was_VBD isolated_VBN from_IN the_DT sputum_NN of_IN a_DT 30-year-old_JJ patient_NN in_IN Novosibirsk_NP ;_: this_DT strain_NN was_VBD susceptible_JJ to_TO all_DT other_JJ agents_NNS tested_VBD ._SENT The_DT cefotaxime_NN MICs_NN for_IN these_DT three_CD strains_NNS were_VBD all_RB 1_CD mug/ml_NN ._SENT Macrolide_NP resistance_NN was_VBD rare_JJ in_IN all_DT areas_NNS tested_VBD ._SENT All_DT pneumococcal_JJ strains_NNS were_VBD susceptible_JJ to_TO telithromycin_NN ,_, levofloxacin_NN ,_, and_CC quinupristin-dalfopristin_NN at_IN the_DT breakpoints_NNS used_VBD ._SENT The_DT MICs_NP of_IN the_DT agents_NNS tested_VBD according_VBG to_TO resistance_NN mechanism_NN are_VBP shown_VBN in_IN Table_NP ._SENT Telithromycin_NP was_VBD the_DT most_RBS active_JJ antibacterial_NN tested_VBN against_IN all_DT strains_NNS of_IN both_DT species_NN ,_, regardless_RB of_IN their_PP$ macrolide_NN resistance_NN mechanism_NN ._SENT The_DT prevalence_NN of_IN erythromycin_NN resistance_NN among_IN S._NP pneumoniae_NNS strains_NNS was_VBD 2.5_CD %_NN (_( 12_CD isolates_NNS )_) ._SENT Most_JJS of_IN the_DT macrolide-resistant_JJ S._NP pneumoniae_NNS were_VBD isolated_VBN from_IN sputum_NN (_( 63_CD %_NN )_) ._SENT The_DT mechanisms_NNS of_IN macrolide_NN resistance_NN were_VBD mef(A)_JJ (_( five_CD isolates_NNS ;_: 41.7_CD %_NN )_) and_CC erm(B)_JJ (_( four_CD isolates_NNS ;_: 33.3_CD %_NN )_) genes_NNS and_CC ribosomal_JJ mutations_NNS (_( three_CD isolates_NNS ;_: 25_CD %_NN )_) in_IN ribosomal_JJ protein_NN L4_NP (_( two_CD isolates_NNS )_) and_CC in_IN 23S_JJ rRNA_NNS (_( one_CD isolate_NN )_) ._SENT Two_CD strains_NNS had_VBD an_DT L4_NP ribosomal_JJ protein_NN gene_NN mutation_NN that_WDT caused_VBD substitution_NN of_IN the_DT three_CD amino_NN acids_NNS GTG_NP by_IN TPS_NP at_IN positions_NNS 69_CD to_TO 71_CD ._SENT Interestingly_RB these_DT two_CD strains_NNS were_VBD two_CD penicillin-resistant_JJ strains_NNS from_IN Smolensk_NP (_( northwest_RB Russia_NP )_) ._SENT As_IN seen_VBN in_IN Fig._NN the_DT PFGE_JJ patterns_NNS of_IN these_DT strains_NNS after_IN digestion_NN with_IN SmaI_NP were_VBD similar_JJ ._SENT One_CD strain_NN ,_, isolated_VBN from_IN the_DT pleural_JJ fluid_NN of_IN a_DT 38-year-old_JJ patient_NN in_IN Ekaterinburg_NP ,_, had_VBD a_DT mutation_NN at_IN position_NN 2059_CD (_( Escherichia_NP coli_NNS numbering_VBG system_NN )_) in_IN domain_NN V_NN of_IN the_DT gene_NN encoding_VBG 23S_JJ rRNA_NN ,_, with_IN replacement_NN of_IN A_DT by_IN G._NP The_DT resistance_NN phenotype_NN of_IN this_DT strain_NN was_VBD similar_JJ to_TO the_DT ML_NP phenotype_NN of_IN three_CD strains_NNS isolated_VBN in_IN the_DT United_NP States_NPS and_CC had_VBD the_DT same_JJ mutation_NN ._SENT The_DT quinupristin-dalfopristin_NN MIC_NN for_IN this_DT isolate_NN was_VBD 0.5_CD mug/ml_NN ,_, while_IN the_DT MICs_NP of_IN quinupristin_NP and_CC dalfopristin_NP were_VBD 8_CD and_CC >128_JJ mug/ml_NN ,_, respectively_RB ._SENT S._NP pyogenes_NNS ._SENT |_SYM Although_IN most_JJS S._NP pyogenes_NNS strains_NNS were_VBD isolated_VBN from_IN the_DT respiratory_JJ tract_NN (_( 69_CD %_NN )_) ,_, a_DT number_NN of_IN strains_NNS ,_, especially_RB those_DT from_IN the_DT northwest_JJ ,_, were_VBD isolated_VBN from_IN wounds_NNS (_( 27_CD %_NN )_) ._SENT S._NP pyogenes_NNS isolates_NNS were_VBD from_IN patients_NNS 2_CD weeks_NNS to_TO 81_CD years_NNS old_JJ ._SENT Most_JJS were_VBD isolated_VBN from_IN children_NNS and_CC young_JJ adults_NNS (_( 63_CD %_NN )_) ._SENT Susceptibility_NN patterns_NNS of_IN S._NP pyogenes_NNS are_VBP presented_VBN in_IN Tables_NP and_NP ._SENT All_DT isolates_NNS were_VBD susceptible_JJ to_TO penicillin_NN G._NP Of_IN 600_CD S._NP pyogenes_NNS isolates_NNS tested_VBD ,_, 66_CD isolates_NNS (_( 11_CD %_NN )_) were_VBD found_VBN to_TO be_VB resistant_JJ to_TO macrolides_NNS ._SENT Erythromycin_NN resistance_NN was_VBD mainly_RB seen_VBN in_IN the_DT Siberia_NP ,_, northwest_RB ,_, and_CC central_JJ regions_NNS ._SENT The_DT MICs_NP of_IN the_DT agents_NNS tested_VBD according_VBG to_TO resistance_NN mechanism_NN are_VBP shown_VBN in_IN Table_NP ._SENT The_DT majority_NN of_IN macrolide-resistant_JJ S._NP pyogenes_NNS strains_NNS were_VBD isolated_VBN from_IN wound_NN (_( 47_CD %_NN )_) and_CC throat_NN (_( 36_CD %_NN )_) specimens_NNS ._SENT Erythromycin_NN resistance_NN was_VBD a_DT result_NN of_IN the_DT presence_NN of_IN the_DT erm(A)_JJ gene_NN subclass_NN erm(TR)_NN in_IN 59_CD isolates_NNS (_( 89.4_CD %_NN )_) or_CC the_DT mef(A)_JJ gene_NN in_IN five_CD isolates_NNS (_( 7.6_CD %_NN )_) ._SENT Except_IN for_IN two_CD strains_NNS the_DT expression_NN of_IN erm(A)_JJ genes_NNS was_VBD inducible_JJ by_IN the_DT double-disk_NN method_NN (_( 96.6_CD %_NN )_) ._SENT The_DT susceptibility_NN rate_NN of_IN telithromycin_NN was_VBD 99.2_CD %_NN ._SENT Five_CD isolates_NNS (_( 7.6_CD %_NN )_) among_IN the_DT 66_CD erythromycin-resistant_JJ S._NP pyogenes_NNS isolates_NNS were_VBD intermediate_JJ to_TO telithromycin_NP (_( MICs_NP ,_, 1_CD mug/ml_NN )_) ;_: two_CD had_VBD constitutive_JJ erm(A)_NN genes_NNS and_CC three_CD had_VBD mef(A)_JJ genes_NNS ._SENT The_DT MICs_NN of_IN erythromycin_NN ,_, azithromycin_NN ,_, and_CC clarithromycin_NN for_IN two_CD strains_NNS with_IN constitutive_JJ erm(A)_NN were_VBD >64_JJ mug/ml_NN ,_, and_CC those_DT of_IN telithromycin_NN were_VBD 1_CD mug/ml_NN ._SENT Two_CD strains_NNS had_VBD no_RB known_VBN erythromycin_NN resistance_NN genes_NNS or_CC mutations_NNS in_IN genes_NNS encoding_VBG 23S_JJ rRNA_NN or_CC ribosomal_JJ proteins_NNS L4_NP or_CC L22_NP ;_: these_DT strains_NNS were_VBD from_IN Yaroslavl_NP (_( central_NN Russia_NP )_) and_CC were_VBD isolated_VBN from_IN throats_NNS of_IN 22-_CD and_CC 40-year-old_JJ patients_NNS ._SENT For_IN these_DT strains_NNS ,_, the_DT MICs_NN of_IN erythromycin_NN ,_, azithromycin_NP ,_, clarithromycin_NP ,_, clindamycin_NN ,_, and_CC telithromycin_NN were_VBD 1_CD ,_, 2_CD to_TO 4_CD ,_, 0.5_CD 0.125_CD ,_, and_CC 0.03_CD to_TO 0.06_CD mug/ml_NN ,_, respectively_RB ._SENT These_DT strains_NNS had_VBD the_DT same_JJ PFGE_NN pattern_NN after_IN digestion_NN with_IN SmaI_NP ._SENT The_DT mechanism_NN of_IN macrolide_NN resistance_NN of_IN these_DT strains_NNS is_VBZ currently_RB under_IN investigation_NN ._SENT Among_IN the_DT strains_NNS with_IN the_DT erm(A)_JJ gene_NN ,_, four_CD PFGE_NP types_NNS containing_VBG more_JJR than_IN one_CD isolate_NN were_VBD characterized_VBN ._SENT Eighty-six_NN per_IN cent_NN of_IN the_DT erm(A)_JJ strains_NNS had_VBD one_CD of_IN these_DT four_CD PFGE_NP patterns_NNS after_IN digestion_NN with_IN SmaI_NP ._SENT Twenty-two_NP strains_NNS were_VBD PFGE_NP type_NN A_NP ,_, 5_CD were_VBD PFGE_NP type_NN B_NP ,_, 6_CD were_VBD PFGE_NP type_NN C_NP ,_, and_CC 18_CD were_VBD PFGE_NP type_NN D._NP Three_NP isolates_VBZ from_IN Smolensk_NP ,_, two_CD from_IN Tumen_NP ,_, and_CC one_CD from_IN Ekaterinburg_NP had_VBD the_DT same_JJ PFGE_NN type_NN ;_: these_DT cities_NNS are_VBP located_VBN far_RB from_IN each_DT other_JJ ._SENT FIG._NN 2_CD ._SENT |_SYM PFGE_NP pattern_NN of_IN three_CD S._NP pneumoniae_NNS PFGE_NN pattern_NN of_IN three_CD S._NP pneumoniae_NNS strains_NNS with_IN ribosomal_JJ mutations_NNS after_IN digestion_NN with_IN SmaI_NP ._SENT Lane_NP 1_CD ,_, strain_NN with_IN mutation_NN in_IN 23S_JJ rRNA_NN ;_: lanes_NNS 2_CD and_CC 3_CD ,_, strains_NNS with_IN mutation_NN in_IN ribosomal_JJ protein_NN L4_NP ._SENT FIG._NN 3_CD ._SENT |_SYM PFGE_NP pattern_NN of_IN two_CD S._NP pyogenes_NNS PFGE_NN pattern_NN of_IN two_CD S._NP pyogenes_NNS strains_NNS from_IN Yaroslavl_NP with_IN unknown_JJ resistance_NN mechanisms_NNS ._SENT FIG._NN 4_CD ._SENT |_SYM PFGE_NP patterns_NNS of_IN S._NP pyogenes_NNS PFGE_NP patterns_NNS of_IN S._NP pyogenes_NNS strains_NNS with_IN the_DT erm(A)_JJ gene_NN ._SENT TABLE_NN 1_CD |_SYM Agar_NP dilution_NN MICs_NN of_IN agents_NNS tested_VBN against_IN S._NP pneumoniae_NNS TABLE_NP 2_CD |_SYM Rates_NNS of_IN susceptibility_NN of_IN S._NP pneumoniae_NNS to_TO various_JJ agents_NNS TABLE_NP 3_CD |_SYM MICs_NN according_VBG to_TO mechanism_NN of_IN resistance_NN in_IN 12_CD macrolide-resistant_JJ S._NP pneumoniae_NNS isolates_VBZ TABLE_NP 4_CD |_SYM Agar_NP dilution_NN MICs_NN of_IN agents_NNS tested_VBN against_IN S._NP pyogenes_NNS TABLE_NP 5_CD |_SYM Rates_NNS of_IN susceptibility_NN of_IN S._NP pyogenes_NNS to_TO various_JJ agents_NNS TABLE_NP 6_CD |_SYM MICs_NN according_VBG to_TO mechanism_NN of_IN resistance_NN in_IN 66_CD macrolide-resistant_JJ S._NP pyogenes_NNS isolates_VBZ In_IN the_DT present_JJ study_NN ,_, a_DT very_RB low_JJ prevalence_NN of_IN drug_NN resistance_NN was_VBD found_VBN for_IN S._NP pneumoniae_NP and_CC S._NP pyogenes_NNS except_IN in_IN Siberia_NP (_( both_CC species_NNS )_) and_CC the_DT northwest_JJ and_CC central_JJ regions_NNS (_( S._NP pyogenes_NNS )_) ._SENT The_DT pneumococci_NNS for_IN which_WDT the_DT penicillin_NN G_NP MICs_NP were_VBD highest_RBS (_( 4_CD to_TO 8.0_CD mug/ml_NN )_) came_VBD from_IN Novosibirsk_NP ,_, a_DT city_NN in_IN south_RB central_JJ Siberia_NP ,_, and_CC two_CD strains_NNS from_IN Smolensk_NP ._SENT The_DT Siberian_JJ isolate_NN was_VBD susceptible_JJ to_TO other_JJ drug_NN classes_NNS ,_, but_CC the_DT Smolensk_NP strain_NN was_VBD macrolide-_NN and_CC azalide-resistant_NN ,_, with_IN mutation_NN in_IN ribosomal_JJ protein_NN L4_NP ._SENT The_DT reason_NN for_IN these_DT geographic_JJ differences_NNS is_VBZ unclear_JJ at_IN present_JJ but_CC may_MD be_VB related_VBN to_TO travel_VB patterns_NNS and/or_CC antibacterial_NN use_NN in_IN the_DT different_JJ parts_NNS of_IN Russia_NP ._SENT This_DT is_VBZ currently_RB under_IN investigation_NN ._SENT Irrespective_RB of_IN resistance_NN to_TO other_JJ drugs_NNS or_CC drug_NN classes_NNS ,_, all_DT pneumococci_NNS were_VBD susceptible_JJ to_TO telithromycin_NN ,_, levofloxacin_NN ,_, and_CC quinupristin-dalfopristin_NP ._SENT It_PP is_VBZ noteworthy_JJ that_IN the_DT low_JJ prevalence_NN of_IN drug-resistant_JJ pneumococci_NNS and_CC S._NP pyogenes_NNS in_IN most_JJS areas_NNS of_IN Russia_NP parallels_VBZ those_DT found_VBD recently_RB by_IN our_PP$ group_NN in_IN Baltic_JJ countries_NNS such_JJ as_IN Lithuania_NP and_CC Latvia_NP (_( P._NP C._NP Appelbaum_NP et_FW al._FW ,_, Abstr_NP ._SENT 40th_JJ Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstracts_VBZ 2153_CD and_CC 2154_CD ,_, 2000_CD )_) ._SENT Data_NNS from_IN the_DT Urals_NP and_CC the_DT southern_JJ part_NN of_IN Russia_NP are_VBP preliminary_JJ and_CC must_MD be_VB confirmed_VBN by_IN testing_VBG more_JJR strains_NNS ._SENT The_DT prevalence_NN of_IN drug_NN resistance_NN in_IN pneumococci_NNS and_CC S._NP pyogenes_NNS throughout_IN the_DT cities_NNS in_IN the_DT Russian_NP Federation_NP studied_VBN is_VBZ currently_RB low_JJ ._SENT However_RB ,_, the_DT apparent_JJ presence_NN of_IN a_DT nidus_NN of_IN increased_VBN resistance_NN in_IN Siberia_NP ,_, as_RB well_RB as_IN a_DT multiresistant_JJ strain_NN from_IN Smolensk_NP ,_, indicates_VBZ potential_JJ for_IN the_DT spread_NN of_IN these_DT organisms_NNS in_IN the_DT future_NN ._SENT The_DT prevalence_NN of_IN macrolide_NN resistance_NN among_IN pneumococci_NNS was_VBD generally_RB low_JJ in_IN all_DT of_IN the_DT regions_NNS of_IN Russia_NP studied_VBD (_( 2.5_CD %_NN )_) ._SENT However_RB ,_, rRNA_NN and_CC ribosomal_JJ protein_NN mutations_NNS were_VBD significant_JJ mechanisms_NNS of_IN macrolide_NN resistance_NN among_IN these_DT isolates_NNS (_( 3_CD of_IN 12_CD )_) ._SENT The_DT prevalence_NN of_IN macrolide_NN resistance_NN was_VBD higher_JJR in_IN S._NP pyogenes_NNS than_IN in_IN S._NP pneumoniae_NNS and_CC was_VBD associated_VBN with_IN four_CD clones_NNS ._SENT Five_CD strains_NNS from_IN three_CD distinct_JJ regions_NNS of_IN Russia_NP were_VBD found_VBN to_TO belong_VB to_TO same_JJ clone_NN ._SENT In_IN summary_NN all_DT pneumococci_NNS and_CC 99.2_CD %_NN of_IN S._NP pyogenes_NNS isolates_NNS ,_, irrespective_RB of_IN their_PP$ erythromycin_NN resistance_NN ,_, were_VBD susceptible_JJ to_TO telithromycin_NN at_IN a_DT breakpoint_NN of_IN 0.5_CD mug/ml_NN ,_, as_RB well_RB as_IN being_VBG uniformly_RB susceptible_JJ to_TO levofloxacin_NN and_CC quinupristin-dalfopristin_NN ._SENT Telithromycin_NP ,_, therefore_RB ,_, has_VBZ considerable_JJ potential_NN for_IN the_DT empirical_JJ treatment_NN for_IN community-acquired_JJ infections_NNS caused_VBN by_IN macrolide-susceptible_JJ and_CC -resistant_JJ S._NP pneumoniae_NP and_CC S._NP pyogenes_NNS ._SENT 